但这种垄断格局，即将被打破，多款在研新药正从作用机制到给药方式，向Vosoritide发起挑战。Ascendis的TransCon-CNP通过包裹技术延长了药物作用时间，实现了周剂给药，目前正处于FDA审批阶段；而BridgeBio的口服药Infigratinib，则从作用机制到用药体验实现全面突破。
🧠 Part 2. 亮点功能实测：挑战“不可能三角”
，详情可参考91视频
const CharType* Content = nullptr;
Discover all the plans currently available in your country
themselves. SRI and, later, their chosen manufacturing partner General Electric